Who owns Fennec Pharmaceuticals Inc?
- Ticker: FENC
- CUSIP Number: 31447p100
Tip: Access positions for across all investors
Analyze quarterly positions in Fennec Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Fennec Pharmaceuticals stock
Who bought or sold Fennec Pharmaceuticals Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Southpoint Capital Advisors | 4.1M | $46M | 0% | Dec 2023 |
|
| venBio Select Advisor | 1.2M | $14M | 0% | Dec 2023 |
|
| Vanguard Group | 1.1M | $13M | 1294% | Dec 2023 |
|
| DG Capital Management | 1.1M | $12M | -6% | Dec 2023 |
|
| AIGH Capital Management | 329k | $3.7M | -12% | Dec 2023 |
|
| Jeffrey L. Gendell | 283k | $3.2M | -1% | Dec 2023 |
|
| Worth Venture Partners | 142k | $1.6M | 53% | Dec 2023 |
|
| 683 Capital Management | 140k | $1.6M | -53% | Dec 2023 |
|
| Lion Point Capital | 110k | $1.2M | 0% | Dec 2023 |
|
| Legato Capital Management | 57k | $635k | 100% | Mar 2024 |
|
| Bank of New York Mellon | 48k | $535k | 5% | Mar 2024 |
|
| Hartford Financial Management | 48k | $532k | 1% | Mar 2024 |
|
| Charles Schwab Investment Management | 42k | $466k | 0% | Dec 2023 |
|
| Bank of America Corporation | 40k | $449k | 26% | Dec 2023 |
|
| Eudaimonia Advisors | 35k | $393k | 8% | Mar 2024 |
|
| Goldman Sachs Group | 31k | $348k | 79% | Dec 2023 |
|
| Wexford Capital | 26k | $296k | 0% | Dec 2023 |
|
| Barclays | 25k | $282k | 625% | Dec 2023 |
|
| UBS Group | 20k | $224k | 100% | Dec 2023 |
|
| Rhumbline Advisers | 20k | $223k | -3% | Dec 2023 |
|
| Bnp Paribas Arbitrage, Snc | 20k | $219k | 18% | Dec 2023 |
|
| Millennium Management | 14k | $161k | 100% | Dec 2023 |
|
| Jump Financial | 14k | $158k | 100% | Dec 2023 |
|
| Jpmorgan Chase & Co | 13k | $147k | 11% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 11k | $127k | 100% | Dec 2023 |
|
| New York State Common Retirement Fund | 11k | $119k | -2% | Dec 2023 |
|
| Mirae Asset Global Investments | 10k | $117k | 0% | Dec 2023 |
|
| Citadel Advisors | 10k | $112k | -63% | Dec 2023 |
|
| MetLife Investment Advisors | 9.7k | $109k | 0% | Dec 2023 |
|
| American International | 9.0k | $101k | 0% | Dec 2023 |
|
| Royal Bank of Canada | 7.1k | $79k | 21% | Dec 2023 |
|
| Wells Fargo & Company | 5.2k | $59k | 26% | Dec 2023 |
|
| Citigroup | 2.7k | $31k | 2352% | Dec 2023 |
|
| State of Wyoming | 2.5k | $28k | 13% | Dec 2023 |
|
| Legal & General Group | 1.7k | $19k | 14% | Dec 2023 |
|
| Summit Investment Advisors | 1.5k | $17k | 0% | Dec 2023 |
|
| Metropolitan Life Insurance Company | 1.0k | $11k | 0% | Dec 2023 |
|
| Amalgamated Bank | 612.00 | $7.0k | -67% | Mar 2024 |
|
| Advisor Group Holdings | 110.00 | $1.2k | 0% | Dec 2023 |
|
| Pnc Financial Services | 87.00 | $976.000800 | 100% | Dec 2023 |
|
| Russell Investments | 48.00 | $539.001600 | -85% | Dec 2023 |
|
| CWM | 8.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Fennec Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Apis Capital Advisors | Sep 2023 | 70k | $526k |
| HighMark Wealth Management | Sep 2023 | 3.0k | $23k |
| Ronald Blue Trust | Sep 2023 | 2.4k | $21k |
| Simplex Trading | Dec 2023 | 12.00 | $0 |